20.38
-0.07
(-0.34%)
At close: January 10 at 8:00:44 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
330,531.00
108,463.00
48,661.00
335,659.00
Operating Expense
504,604.00
527,230.00
449,207.00
344,412.00
272,941.00
Operating Income
-504,604.00
-196,699.00
-340,744.00
-295,751.00
62,718.00
Net Non Operating Interest Income Expense
62,604.00
51,505.00
14,774.00
4,595.00
9,241.00
Pretax Income
-427,463.00
-145,194.00
-325,970.00
-291,156.00
71,959.00
Tax Provision
--
30.00
21.00
-575.00
823.00
Net Income Common Stockholders
-427,493.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
Diluted NI Available to Com Stockholders
-427,493.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
Basic EPS
-2.76
-1.06
-2.60
-2.39
0.65
Diluted EPS
-2.76
-1.06
-2.60
-2.39
0.63
Basic Average Shares
156,505.74
137,370.90
125,530.70
121,524.80
108,974.14
Diluted Average Shares
156,505.74
137,370.90
125,530.70
121,524.80
112,703.11
Total Operating Income as Reported
-490,067.00
-196,699.00
-340,744.00
-295,751.00
62,718.00
Total Expenses
504,604.00
527,230.00
449,207.00
344,412.00
272,941.00
Net Income from Continuing & Discontinued Operation
-427,493.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
Normalized Income
-442,030.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
Interest Income
62,604.00
51,505.00
14,774.00
4,595.00
9,241.00
Net Interest Income
62,604.00
51,505.00
14,774.00
4,595.00
9,241.00
EBIT
-504,604.00
-196,699.00
-340,744.00
-295,751.00
62,718.00
EBITDA
-496,054.00
-179,973.00
-330,361.00
-287,158.00
71,249.00
Reconciled Depreciation
8,550.00
16,726.00
10,383.00
8,593.00
8,531.00
Net Income from Continuing Operation Net Minority Interest
-427,493.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
Total Unusual Items Excluding Goodwill
14,537.00
--
--
--
--
Total Unusual Items
14,537.00
--
--
--
--
Normalized EBITDA
-510,591.00
-179,973.00
-330,361.00
-287,158.00
71,249.00
Tax Rate for Calcs
--
0.00
0.00
0.00
0.00
12/31/2020 - 11/7/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ENBI.CN Entheon Biomedical Corp.
0.2750
+7.84%
THAR Tharimmune, Inc.
2.0500
-5.53%
BRTX BioRestorative Therapies, Inc.
1.6300
-3.55%
COYA Coya Therapeutics, Inc.
5.77
-4.94%
GTBP GT Biopharma, Inc.
2.6500
+3.92%
QNCX Quince Therapeutics, Inc.
1.7900
-4.79%
KZIA Kazia Therapeutics Limited
1.5800
-5.95%
TELO Telomir Pharmaceuticals, Inc.
4.1100
-4.42%
IGMS IGM Biosciences, Inc.
2.0900
-66.29%
IMNN Imunon, Inc.
0.8999
-1.06%